Table: Daito - 6-MTH group results
Jan 12 (Reuters)-
Daito Pharamaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Nov 30, 2017 Nov 30, 2016 May 31, 2018
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 20.45 19.22 40.50
(+6.4 pct) (+4.9 pct) (+6.6 pct)
Operating 2.27 2.13 4.10
(+6.5 pct) (+14.9 pct) (+7.0 pct)
Recurring 2.30 2.08 4.15
(+10.6 pct) (+10.4 pct) (+7.0 pct)
Net 1.59 1.42 2.85
(+11.5 pct) (+12.3 pct) (+7.3 pct)
EPS 126.82 yen 113.79 yen 227.74 yen
Ann Div 33.00 yen 30.00 yen
-Q2 div 15.00 yen 15.00 yen
-Q4 div 18.00 yen 15.00 yen
NOTE - Daito Pharamaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4577.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on Daito Pharmaceutical
See all newsTo Buy Back Up To 4.4% Of Own Shares Worth 2 Billion Yen
Table: Daito Pharmaceutical -Q1 group results
Execution Of JV And Share Transfer Agreement For Transfer Of Kyorin Pharmaceutical's Generic Drug Business To JV By Daito, Meiji Seika Pharma And Dbj
Table: Daito -2025/26 parent results
Table: Daito -2025/26 group results